Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLJDT and Thalidomide in Multiple Myeloma Maintenance Therapy
NCT02467647Phase 1Unknown
- Sponsor
- Wuhan University
- Start
- Jan 2015
- Primary completion
- Dec 2018
- Modality
- HM (Herbal Medicine), TCM (Traditional Chinese Medicine)
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Huanglian Jiedu Decoction in multiple myeloma (MM), sponsored by Wuhan University. Primary endpoint: Overall Survival at 6 months. Status: unknown.
02
Drugs
Huanglian Jiedu Decoction
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02467647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02467647.